Incannex Healthcare Funds Sleep Apnea Research via AASM Foundation Partnership
Summary
Incannex Healthcare Inc. has announced a partnership with the American Academy of Sleep Medicine (AASM) Foundation, joining its Corporate Recognition Program and sponsoring a Focused Projects Grant for junior investigators in sleep apnea research. This collaboration enhances Incannex's credibility and visibility within the sleep medicine community, aligning the company with a respected foundation as it develops IHL-42X for obstructive sleep apnea. The partnership also serves to highlight the ongoing positive progress of IHL-42X, which has received FDA Fast Track designation and is advancing towards patient dosing in the DReAMzz Phase 2 dose-optimization study in the coming months. This strategic engagement, following recent significant cash raises and a strengthened balance sheet, underscores the company's commitment to the field and its lead drug candidate. Investors should watch for updates on the DReAMzz study as a key near-term catalyst.
At the time of this announcement, IXHL was trading at $2.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.2M. The 52-week trading range was $2.40 to $49.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.